Literature DB >> 20037429

[A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].

Junzo Shimizu1, Shoho Hayashi, Keizo Dono, Taku Yasumoto, Masahiro Zenitani, Kouji Munakata, Noriyuki Watanabe, Kaori Takamoto, Yoshinori Kagawa, Taishi Hata, Kensyu Kawanishi, Kimimasa Ikeda, Junya Fujita, Kenzo Akagi, Masashi Kitada, Takashi Shimano.   

Abstract

Primary liver cancer with lymph node metastasis was recognized as poor prognosis. We herein report a case of post operative lymph node recurrence treated with UFT. A 74-year-old man with a huge mass lesion in the right liver with para Aortic lymph node metastasis admitted our hospital in April 2007. Extended right lobe hepatectomy and lymph node dissection were performed in May. A histological examination of the resected specimen showed a combined hepatocellular-cholangiocarcinoma with three lymph node metastasis. Computed tomography(CT)revealed intra hepatic metastasis (S3) and right adrenal grand metastasis 5 months after surgery. Transarterial embolization (TAE) and right adrenalectomy were performed for each metastasis. CT revealed a lymph node metastasis at the right side of infra vena cava 1 year after surgery. He was treated by oral administration of UFT (200 mg/day). The AFP and PIVKA-II value gradually decreased after administration of UFT. The size of lymph node metastasis became small confirmed by CT. But the AFP and PIVKA-II value increased 1 year and 7 months after surgery. TAE was performed against lymph node metastasis 1 year and 9 months after surgery. This case suggests UFT is useful for suppressing the growth of the lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20037429

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

Review 1.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

2.  Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.

Authors:  Satoshi Kobayashi; Takeshi Terashima; Satoshi Shiba; Yukio Yoshida; Ikuhiro Yamada; Shouta Iwadou; Shigeru Horiguchi; Hideaki Takahashi; Eiichiro Suzuki; Michihisa Moriguchi; Kunihiro Tsuji; Taiga Otsuka; Akinori Asagi; Yasushi Kojima; Ryoji Takada; Chigusa Morizane; Nobumasa Mizuno; Masafumi Ikeda; Makoto Ueno; Junji Furuse
Journal:  Cancer Sci       Date:  2018-06-27       Impact factor: 6.716

Review 3.  Treatment of Combined Hepatocellular and Cholangiocarcinoma.

Authors:  Simona Leoni; Vito Sansone; Stefania De Lorenzo; Luca Ielasi; Francesco Tovoli; Matteo Renzulli; Rita Golfieri; Daniele Spinelli; Fabio Piscaglia
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.